ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33-4-78-74-44-38
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees172
Next Earnings DateN/A
OptionableNot Optionable
Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions
What is Erytech Pharma's stock symbol?
Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."
What is the consensus analysts' recommendation for Erytech Pharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Erytech Pharma.
Has Erytech Pharma been receiving favorable news coverage?
News articles about ERYP stock have trended positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Erytech Pharma earned a news impact score of 2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Erytech Pharma.
Are investors shorting Erytech Pharma?
Erytech Pharma saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,700 shares, a decrease of 19.0% from the June 30th total of 2,100 shares. Based on an average daily volume of 600 shares, the short-interest ratio is currently 2.8 days. Currently, 0.0% of the shares of the company are short sold. View Erytech Pharma's Current Options Chain.
Who are some of Erytech Pharma's key competitors?
Some companies that are related to Erytech Pharma include Prevail Therapeutics (PRVL), AVITA MED LTD/S (AVMXY), Gritstone Oncology (GRTS), Replimune Group (REPL), Scholar Rock (SRRK), Solid Biosciences (SLDB), CASI Pharmaceuticals (CASI), PDL BioPharma (PDLI), BioCryst Pharmaceuticals (BCRX), Harpoon Therapeutics (HARP), La Jolla Pharmaceutical (LJPC), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), ADMA Biologics (ADMA) and Compugen (CGEN).
What other stocks do shareholders of Erytech Pharma own?
Who are Erytech Pharma's key executives?
Erytech Pharma's management team includes the folowing people:
- Mr. Gil Beyen, Chairman & CEO (Age 57)
- Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 40)
- Mr. Eric Soyer, CFO & COO (Age 53)
- Dr. Alexander Scheer, Chief Scientific Officer (Age 57)
- Naomi Eichenbaum, Director Investor Relations
When did Erytech Pharma IPO?
(ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.
How do I buy shares of Erytech Pharma?
Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Erytech Pharma's stock price today?
One share of ERYP stock can currently be purchased for approximately $5.20.
How big of a company is Erytech Pharma?
Erytech Pharma has a market capitalization of $93.29 million. The company earns $-45,140,000.00 in net income (profit) each year or $2.44 on an earnings per share basis. Erytech Pharma employs 172 workers across the globe.View Additional Information About Erytech Pharma.
What is Erytech Pharma's official website?
How can I contact Erytech Pharma?
Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected]
MarketBeat Community Rating for Erytech Pharma (NASDAQ ERYP)
MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote "Outperform" if you believe ERYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
